Janux Therapeutics (NASDAQ:JANX) Price Target Lowered to $26.00 at Piper Sandler

Key Points

• Piper Sandler lowered its price target on Janux Therapeutics to $26 (from $30) while keeping an "overweight" rating, implying roughly an 83% upside from the current share price of $14.20.
• Analysts remain generally positive with a consensus rating of Moderate Buy and an average price target of $47.83 (1 Strong Buy, 9 Buy, 3 Hold, 2 Sell), though several firms including Guggenheim and Wedbush recently trimmed their targets.
• Shares traded at $14.20 with a one-year range of $12.12–$35.34 and a market cap of ~$865M; Janux reported quarterly EPS of ($0.39), beating estimates of ($0.52) while revenue of $3.73M missed the $4.36M consensus.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) had its target price reduced by stock analysts at Piper Sandler from $30.00 to $26.00 in a research note issued on Friday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Piper Sandler's price target would suggest a potential upside of 83.16% from the company's current price.

A number of other research analysts have also recently issued reports on JANX. Truist Financial upgraded shares of Janux Therapeutics to a "strong-buy" rating in a report on Monday. Guggenheim dropped their price target on shares of Janux Therapeutics from $68.00 to $58.00 and set a "buy" rating on the stock in a research report on Friday. Wall Street Zen raised Janux Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, April 5th. Wedbush dropped their price objective on Janux Therapeutics from $45.00 to $36.00 and set an "outperform" rating on the stock in a research note on Friday. Finally, Clear Str downgraded shares of Janux Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $47.83.

Janux Therapeutics Stock Performance

Shares of NASDAQ JANX traded down $0.35 during midday trading on Friday, hitting $14.20. 272,413 shares of the stock traded hands, compared to its average volume of 1,213,634. Janux Therapeutics has a one year low of $12.12 and a one year high of $35.34. The business has a 50 day moving average price of $14.35 and a two-hundred day moving average price of $17.45. The company has a market cap of $865.33 million, a PE ratio of -7.73 and a beta of 2.58.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Thursday, May 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.52) by $0.13. The firm had revenue of $3.73 million during the quarter, compared to the consensus estimate of $4.36 million. As a group, equities research analysts forecast that Janux Therapeutics will post -2.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Janux Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in JANX. Nano Cap New Millennium Growth Fund L P purchased a new stake in Janux Therapeutics during the fourth quarter worth about $34,000. Osaic Holdings Inc. grew its position in shares of Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company's stock valued at $80,000 after acquiring an additional 3,037 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in shares of Janux Therapeutics during the 4th quarter valued at approximately $51,000. Tower Research Capital LLC TRC increased its stake in shares of Janux Therapeutics by 175.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company's stock worth $91,000 after purchasing an additional 2,502 shares during the last quarter. Finally, Winthrop Capital Management LLC purchased a new stake in shares of Janux Therapeutics during the 3rd quarter worth approximately $106,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.